Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-10-05FDA Approved: LENALIDOMIDE — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Zydus Pharmaceuticals USA Inc. under ANDA210154, updating the lena…
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]
A clinical trial evaluating Ublituximab and Umbralisib with CHOP followed by U2 maintenance in newly diagnosed mantle cell lymphoma was term…
-
CLINICAL_TRIALS trial_result · 2023-09-21Clinical Trial Update: Allo HSCT Using RIC for Hematological Diseases [Phase 2]
Phase 2 trial evaluating allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for various hematologic dise…
-
CLINICAL_TRIALS trial_result · 2023-08-21Clinical Trial Update: ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) [Phase 2]
A Phase 2 clinical trial update evaluating ABT-199 and Ibrutinib for Mantle Cell Lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-08-16Clinical Trial Update: Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating sequential chemo-radiotherapy followed by autologous transplantation in untreated advanced mantle cell l…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma [Phase 2]
Phase II study of AT7519M, a CDK inhibitor, in patients with relapsed mantle cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating bortezomib plus gemcitabine in relapsed mantle cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-08-04Clinical Trial Update: Bortezomib in Treating Patients With Mantle Cell Lymphoma [Phase 2]
Phase 2 trial update evaluating bortezomib in mantle cell lymphoma.
-
CLINICAL_TRIALS trial_result · 2023-07-25Clinical Trial Update: Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma [Phase 3]
Phase 3 trial investigating autologous anti-CD19 CAR-T cells given with a BTK inhibitor for B cell lymphomas, with an unspecified status.
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant [Phase 1, Phase 2]
This update reports results from a Phase 1/2 clinical trial of a gene therapy for HIV-related lymphomas in patients undergoing stem cell tra…
-
CLINICAL_TRIALS trial_result · 2023-07-13Clinical Trial Update: Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects [Phase 1, Phase 2]
Phase I/II trial update for TL-895 with navtemadlin in treatment-naïve and relapsed/refractory B cell malignancies, including CLL/SLL and re…
-
CLINICAL_TRIALS trial_result · 2023-06-09Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]
Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) [Phase 1, Phase 2]
A clinical trial update for ICP-022 in relapsed/refractory mantle cell lymphoma across Phase 1 and Phase 2 stages.
-
FDA approval · 2023-06-05FDA Approved: BENDAMUSTINE — Original Application (Meitheal Pharmaceuticals Inc.)
The FDA approved the original application for Bendamustine HCl from Meitheal Pharmaceuticals Inc., sanctioning a generic version of bendamus…
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission [Phase 1, Phase 2]
A clinical trial assessing ixazomib and rituximab after stem cell transplant in Mantle Cell Lymphoma in remission, spanning Phase 1 and Phas…
-
CLINICAL_TRIALS withdrawal · 2023-04-21Clinical Trial Update: A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 3]
A Phase 3 trial combining Zilovertamab with Ibrutinib for relapsed or refractory mantle cell lymphoma has been withdrawn.
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for lenalidomide (ANDA211022), authorizing the marketing of a generic lenalidomide prod…
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for lenalidomide submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-03-24FDA Approved: LENALIDOMIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Lenalidomide submitted by Aurobindo Pharma Limited to support the continued availability of …
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma [Phase 2]
Phase 2 trial investigating a combination of bortezomib, cytarabine, and dexamethasone in mantle cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2023-03-17Clinical Trial Update: Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Relapsed/Refractory Follicular and Aggressive B-cell Lymphoma [Phase 1, Phase 2]
Clinical trial updates the combination of obinutuzumab with lenalidomide for relapsed/refractory follicular and aggressive B-cell lymphomas,…
-
CLINICAL_TRIALS trial_result · 2023-03-16Clinical Trial Update: TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
Phase 1/2 trial update for TC-110 T cells in adults with relapsed or refractory non-Hodgkin lymphoma or acute lymphoblastic leukemia (comple…
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic lenalidomide (LENALIDOMIDE) under ANDA211846.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Lenalidomide from Mylan Pharmaceuticals as an original application (ANDA), marking the approval of a generic lenalidomide.
-
FDA approval · 2023-03-06FDA Approved: LENALIDOMIDE — Original Application (Aurobindo Pharma Limited)
FDA approved Lenalidomide as a generic product under an original application from Aurobindo Pharma Limited.